Drug:  | 
         BIIB021 (CNF2024)  | 
       |||
|---|---|---|---|---|
Trial:  | 
         An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment  | 
       |||
| Conditions: | Gastrointestinal Stromal Tumor | |||
Trial Status:  | 
         Completed  | 
       |||
Mayo Clinic, Rochester       | 
      
Principal Investigator:  | 
        |
|---|---|
Contact:  | 
        |
Activation Status of this Site:  | 
        Closed | 
Notes about this Site:  | 
        |
 Mayo Clinic, Rochester Website:  | 
        http://clinicaltrials.mayo.edu/dspSubthemes.cfm?theme_id=3 | 
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.